1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating Breast Cancer Cell Lines
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F22%3A10458811" target="_blank" >RIV/00216208:11160/22:10458811 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ulkjwIeHJF" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ulkjwIeHJF</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/1385272827666230215141854" target="_blank" >10.2174/1385272827666230215141854</a>
Alternative languages
Result language
angličtina
Original language name
1,3,5 and 1,2,4-triazines as Potent Scaffolds for Molecules Potentially Attenuating Breast Cancer Cell Lines
Original language description
Breast cancer was diagnosed in around 2.3 million women in 2020. Owing to the alarming rise in the incidence of breast cancer, newer small molecules with targeted therapy are the need of the hour. A plethora of small molecules has been approved by the USFDA in the past few years. Triazine is a six-membered aromatic nitrogen heterocyclic molecule that was investigated for its various types of biological activities specially anticancer activity. Triazines are studied in many derivatives having remarkable anti-tumor activity as reported in this literature. Triazines are reported to possess a variety of biological activities and have been widely investigated as a scaffold for developing newer anti-tumor agents with an ability to inhibit various types of cancers, including breast cancers. Triazine derivatives show anticancer activity by inhibiting various targets like mTOR- kinase, PIP3-kinase, epidermal growth factor, etc. A limited number of triazine derivatives have also been clinically used for the treatment of breast cancer. A detailed study of the literature available on various derivatives of triazines with primary applicability as cytotoxic to breast cancer cell was carried out and is presented in this review. A total of 66 structurally diverse triazines have been reported in this review along with the structural features responsible for activity against various breast cancer cell lines. The primary amino residues to which the triazine based molecules bind in the estrogen receptor alpha and epidermal growth factor receptor 2, as found in various docking studies have also been detailed in the review.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Organic Chemistry
ISSN
1385-2728
e-ISSN
1875-5348
Volume of the periodical
26
Issue of the periodical within the volume
24
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
15
Pages from-to
2188-2202
UT code for WoS article
000958785800003
EID of the result in the Scopus database
—